Browse News

Found 5,784 articles

• PDS Biotech Announces PDS0101 Combined with Chemoradiotherapy Associated with Rapid Decline in Circulating Tumor DNA (ctDNA/cfDNA)

  10/2/2023

  PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company) today announced data demonstrating lead candidate PDS0101 in combination with standard-of-care (SOC) chemoradiotherapy (CRT) was associated with a rapid decline in human papillomavirus (HPV) circulating cell-free DNA (cfHPV-DNA), a potential predictive biomarker of treatment response.

• Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

  9/29/2023

  Innovent Biologics, Inc. and IASO Bio announced updated long-term follow-up data from two studies for BMCA CAR-T.

• Interim results for the six months ended 30 June 2023

  9/29/2023

  Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain, announces its unaudited interim results for the six months ended 30 June 2023 which will also be made available on the Company’s website at www.biodexapharma.com.

• NANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer

  9/28/2023

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced new clinical data from a Phase 1 study evaluating radiotherapy-activated NBTXR3 for patients with pancreatic ductal adenocarcinoma (PDAC).

• ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors

  9/28/2023

  ImmunoGenesis, a clinical-stage biotechnology company developing science-driven immunotherapies, today announced the first patient has been dosed in the company's Phase 1a/1b clinical trial of its lead candidate, IMGS-001, at The University of Texas MD Anderson Cancer Center in Houston, Texas.

• IASO Bio Presents Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

  9/28/2023

  IASO Bio and Innovent Biologics, Inc. announced updated long-term follow-up data from two studies for BMCA CAR-T.

• BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting

  9/27/2023

  BeyondSpring Inc. announced the presentation of a poster at the Society for Immunotherapy of Cancer's 38th Annual Meeting, taking place on November 3 through 5 in San Diego, CA.

• Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

  9/27/2023

  Affimed N.V. announced that an abstract with a comparison of NK cell redirected by the Company’s innate cell engagers versus CAR-NK cells has been accepted for poster presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer, which will be held on November 1-5, 2023 in San Diego, California.

• XNK Therapeutics presented two posters at the NK2023 conference in Oslo

  9/27/2023

  XNK Therapeutics AB announced that two posters, regarding bladder cancer and acute myeloid leukemia respectively, was presented at the 20th Meeting of the Society for Natural Immunity in Oslo, Norway, in September.

• Venatorx Pharmaceuticals to Present at IDWeek 2023

  9/27/2023

  Venatorx Pharmaceuticals today announced seven presentations during IDWeek 2023, October 11-15, 2023, in Boston, MA.

• Inspire Medical Systems, Inc. Announces Events at International Surgical Sleep Society and American Academy of Otolaryngology – Head and Neck Surgery Meetings

  9/26/2023

  Inspire Medical Systems, Inc. announced key events at the International Surgical Sleep Society and American Academy of Otolaryngology meetings in Nashville, TN, September 29 through October 4.

• Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer

  9/26/2023

  Candel Therapeutics, Inc. today announced updated activity data from its ongoing, open-label, phase 2 clinical trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy.

• NANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023

  9/26/2023

  NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today provided an update on operational progress and announced its half year financial results for the six-month period ended June 30, 2023.

• JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer

  9/21/2023

  Collaboration leverages JURA Bio’s T cell receptor (TCR) discovery platform to discover and develop innovative therapies by applying AI and machine learning.

• Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031

  9/21/2023

  Antengene Corporation Limited today announced that a Phase I study of the best-in-class anti-CD24 antibody, ATG-031, has been approved by the Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center in Houston, Texas, the United States. 

• Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

  9/21/2023

  Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.

• Endo Presents New Data at the American Orthopaedic Foot & Ankle Society Annual Meeting

  9/21/2023

  Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar fibromatosis will be presented during the American Orthopaedic Foot & Ankle Society's (AOFAS) annual scientific meeting.

• LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer

  9/20/2023

  LIXTE Biotechnology Holdings, Inc. ( Nasdaq: LIXT ) (“LIXTE”), today announced a Phase 1b collaborative clinical trial to assess whether adding Lixte’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).

• Alloy Therapeutics Announces Scientific Advisory Board to Drive Roadmap of Biotherapeutic Discovery Platform Innovation

  9/20/2023

  Alloy Therapeutics, a biotechnology ecosystem company, announced the formation of its scientific advisory board (SAB) that includes a group of renowned experts in fields spanning immunology, protein engineering, T cell receptor (TCR) modalities, and more.

• AuraVax Therapeutics recognizes its academic collaborator at the University of Houston for address at Keystone Conference

  9/19/2023

  AuraVax Therapeutics, Inc. today announced that their partners at the University of Houston presented data at Keystone Symposia: Vaccinology During and After COVID-19 taking place from September 17-20, 2023.